RRoche Read More $15 billion deal: Roche bets on China — and questions Germany’s future2026-10-20 Why it matters: Roche is expanding its collaboration with Chinese pharmaceutical company Hansoh. A year after their first…
CChubb Read More Chubb Wealth and Hamilton Lane Form Partnership to Expand Access to Private Markets in Hong Kong2026-10-12 HONG KONG, Oct. 12, 2026 /PRNewswire/ — Chubb Wealth, Chubb Group’s wealth management platform, together with leading private…
RRoche Read More Roche taps Chinese biotech Defand in reported $1B deal2026-10-08 Why it matters: The Swiss drugmaker is buying access to a discovery platform, with Defand tasked with finding…
NNovartis Read More Novartis bets up to $7.8B on Abogen’s mRNA autoimmune therapy2026-10-02 Why it matters: The approach could offer a simpler way to target the B cells that drive some…
NNovartis Read More Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs2026-10-02 Includes worldwide license to ABO2203, Abogen’s mRNA-encoded CD19xCD3 T-Cell Engager Agreement also gives Novartis exclusive options to license other…
NNovartis Read More Novartis licenses BoomRay radioligand asset for $900M2026-09-22 By the numbers: BoomRay will receive an undisclosed upfront payment and is eligible for development, regulatory and sales…
RRoche Read More Roche taps Dualitas in $1B bispecific deal2026-09-17 Why it matters: Bispecific antibodies, long concentrated in oncology, are increasingly moving into autoimmune and inflammatory diseases. Roche…
RRoche Read More Roche reloads B-cell strategy with $1.53B Simcere deal2026-09-02 Why it matters: The Swiss pharma is doubling down on therapies that achieve deeper B-cell depletion, an increasingly…
RRoche Read More Roche licenses Hanmi obesity drug for up to $2.3B2026-08-24 Why it matters: The agreement adds another mechanism to Roche’s growing obesity pipeline as drugmakers look beyond weight…
RRoche Read More Genentech signs $515m breast cancer deal with Astex2026-07-06 By the numbers: The R&D deal with Roche’s Genentech is worth more than $515 million plus royalties and…
RRoche Read More Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases2026-06-26 SAN DIEGO, May 19, 2020 /PRNewswire/ — Vividion Therapeutics, a biotechnology company discovering and developing highly selective small…
NNovartis Read More Novartis signs up to $1.9bn deal to tap Antares’ undruggable-target engine2026-06-25 Why it matters: The deal is a fresh validation point for Antares, a Scorpion Therapeutics spinout built around…